Testing NALIRIFOX for advanced appendix and small intestine cancer
Part of Cancer clinical trials.
This trial tests a combination of four chemotherapy drugs (NALIRIFOX) as a first treatment for people with advanced appendix or small intestine cancer. It aims to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have advanced (spread) appendix or small intestine cancer (mucinous or non-mucinous type).
- Your cancer can be measured on scans (like CT or MRI).
- You are still active enough to do light work or everyday tasks (ECOG 0-1).
- Your doctor expects you to live at least 6 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) as a first treatment for people with locally advanced pancreatic cancer that hasn't spread. The goal is to see if it can shrink the tumor and improve outcomes.
This trial tests whether a combination of chemotherapy drugs (NALIRIFOX) plus targeted therapy works better than another standard combination (FOLFOX) plus targeted therapy for people with metastatic colorectal cancer who haven't had treatment yet. It aims to find a more effective first treatment option.
This trial tests a combination chemotherapy called NALIRIFOX as a second treatment for people with advanced high-grade neuroendocrine cancers. The goal is to see if it can help when the first treatment didn't work.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) for people with advanced small bowel adenocarcinoma that cannot be surgically removed. It is for those who have not yet had treatment for their advanced cancer, except possibly one cycle of FOLFOX.
This trial tests a new drug combination (NALIRIFOX plus immunotherapy) followed by radiation, compared to NALIRIFOX alone, as a way to shrink pancreatic tumors that haven't spread and make them removable. It's for people who haven't had any previous cancer treatment.
This trial is testing a drug combination called NalIriFOx as the first treatment for people with pancreatic cancer that has spread. The goal is to see if it is safe and works well over the long term.
Hear when a new Advanced Small Intestine Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.